- Target disease: VL
- Main partners (since project start): Takeda Pharmaceutical Company Ltd, Japan; WuXi AppTech, China; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; Pfizer, UK; Sandexis, UK.
- Project start: February 2012
- Funding (since project start): Global Health Innovative Technology (GHIT) Fund, Japan.
Compound mining of well-annotated chemical compound libraries has been used to identify a new class of compounds active against VL. In June 2014, the first in vivo proof of concept for VL series 12 (aminopyrazoles) from Pfizer was achieved in the hamster early curative model of VL. An initial compound gave 93% and 95% reductions in parasitaemia in liver and spleen respectively after five days oral dosing at 50mg/kg BID, with a subsequent compound showing even better in vivo activity (>99% reduction in parasitaemia in both liver and spleen).
Last update: February 2017